{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:14:58Z","timestamp":1793373298198,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Branch Center of National Clinical Research Center for Obstetric and Gynecologic Diseases","award":["S2024KJCXG0001"],"award-info":[{"award-number":["S2024KJCXG0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-01966-6","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:08:24Z","timestamp":1770199704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Repurposing trifluoperazine as a potential therapeutic agent for ovarian cancer: mechanistic insight via SRC\/PI3K\/AKT signaling pathway inhibition"],"prefix":"10.1186","volume":"19","author":[{"given":"Quan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"20","key":"1966_CR1","doi-asserted-by":"publisher","first-page":"15077","DOI":"10.3390\/ijms242015077","volume":"24","author":"E Azzalini","year":"2023","unstructured":"Azzalini E, Stanta G, Canzonieri V, Bonin S. Overview of tumor heterogeneity in high-grade serous ovarian cancers. Int J Mol Sci. 2023;24(20):15077. https:\/\/doi.org\/10.3390\/ijms242015077.","journal-title":"Int J Mol Sci"},{"key":"1966_CR2","doi-asserted-by":"publisher","first-page":"1376873","DOI":"10.3389\/fonc.2024.1376873","volume":"14","author":"H Pan","year":"2024","unstructured":"Pan H, Xu R, Zhang Y. Role of SPRY4 in health and disease. Front Oncol. 2024;14:1376873. https:\/\/doi.org\/10.3389\/fonc.2024.1376873.","journal-title":"Front Oncol"},{"issue":"4","key":"1966_CR3","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3390\/curroncol31040144","volume":"31","author":"G Vivod","year":"2024","unstructured":"Vivod G, Merlo S, Kovacevic N. High-grade serous ovarian cancer during pregnancy: from diagnosis to treatment. Curr Oncol. 2024;31(4):1920\u201335. https:\/\/doi.org\/10.3390\/curroncol31040144.","journal-title":"Curr Oncol"},{"issue":"10","key":"1966_CR4","doi-asserted-by":"publisher","first-page":"e30561","DOI":"10.7759\/cureus.30561","volume":"14","author":"UM Zamwar","year":"2022","unstructured":"Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian Cancer. Cureus. 2022;14(10):e30561. https:\/\/doi.org\/10.7759\/cureus.30561.","journal-title":"Cureus"},{"issue":"1","key":"1966_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12920-024-01917-4","volume":"17","author":"L Tang","year":"2024","unstructured":"Tang L, Ye H, Chen L, Dong W, Hu X, Yu L. Tumorigenic role of Pak4 in ovarian cancer and its correlation with immune infiltration. BMC Med Genomics. 2024;17(1):148. https:\/\/doi.org\/10.1186\/s12920-024-01917-4.","journal-title":"BMC Med Genomics"},{"issue":"16","key":"1966_CR6","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.3390\/cancers13164029","volume":"13","author":"S Mu\u00f1oz-Galv\u00e1n","year":"2021","unstructured":"Mu\u00f1oz-Galv\u00e1n S, Carnero A. Leveraging genomics, transcriptomics, and epigenomics to understand the biology and chemoresistance of ovarian cancer. Cancers (Basel). 2021;13(16):4029. https:\/\/doi.org\/10.3390\/cancers13164029.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1966_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s13046-019-1494-3","volume":"38","author":"R Zhang","year":"2019","unstructured":"Zhang R, Shi H, Ren F, Feng W, Cao Y, Li G, et al. MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt\/catenin beta and MEK\/ERK signaling pathways. J Exp Clin Cancer Res. 2019;38(1):494. https:\/\/doi.org\/10.1186\/s13046-019-1494-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"1966_CR8","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s00705-022-05555-y","volume":"167","author":"LE Piccini","year":"2022","unstructured":"Piccini LE, Castilla V, Damonte EB. Inhibition of dengue virus infection by trifluoperazine. Arch Virol. 2022;167(11):2203\u201312. https:\/\/doi.org\/10.1007\/s00705-022-05555-y.","journal-title":"Arch Virol"},{"issue":"3","key":"1966_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1134\/S1990519X22030075","volume":"16","author":"LS Milenina","year":"2022","unstructured":"Milenina LS, Krutetskaya ZI, Antonov VG, Krutetskaya NI. Sigma-1 receptor ligands chlorpromazine and trifluoperazine attenuate Ca2+ responses in rat peritoneal macrophages. Cell Tissue Biol. 2022;16(3):233\u201344. https:\/\/doi.org\/10.1134\/S1990519X22030075.","journal-title":"Cell Tissue Biol"},{"key":"1966_CR10","doi-asserted-by":"publisher","first-page":"153473542412594","DOI":"10.1177\/15347354241259416","volume":"23","author":"T Jung","year":"2024","unstructured":"Jung T, Cheon C. Synergistic and additive effects of herbal medicines in combination with chemotherapeutics: a scoping review. Integr Cancer Ther. 2024;23:15347354241259416. https:\/\/doi.org\/10.1177\/15347354241259416.","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"1966_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1124\/mol.114.096941","volume":"87","author":"A Pulkoski-Gross","year":"2015","unstructured":"Pulkoski-Gross A, Li J, Zheng C, Li Y, Ouyang N, Rigas B, et al. Repurposing the antipsychotic trifluoperazine as an antimetastasis agent. Mol Pharmacol. 2015;87(3):501\u201312. https:\/\/doi.org\/10.1124\/mol.114.096941.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"1966_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/cancers12061607","volume":"12","author":"M McMullen","year":"2020","unstructured":"McMullen M, Karakasis K, Madariaga A, Oza AM. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer. Cancers. 2020;12(6):1607. https:\/\/doi.org\/10.3390\/cancers12061607.","journal-title":"Cancers"},{"issue":"12","key":"1966_CR13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1164\/rccm.202207-1437ED","volume":"206","author":"G Sgalla","year":"2022","unstructured":"Sgalla G, Richeldi L. Better to be an agnostic than a believer (at least in pulmonary fibrosis). Am J Respir Crit Care Med. 2022;206(12):1439\u201340. https:\/\/doi.org\/10.1164\/rccm.202207-1437ED.","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"1966_CR14","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1080\/14786419.2023.2247536","volume":"38","author":"XY Wang","year":"2024","unstructured":"Wang XY, Wang YJ, Hou ZL, Guo BW, Wang RQ, Liu Q, et al. Ingenane-type diterpenoids inhibit non-small cell lung cancer cells by regulating SRC\/PI3K\/Akt pathway. Nat Prod Res. 2024;38(19):3460\u20135. https:\/\/doi.org\/10.1080\/14786419.2023.2247536.","journal-title":"Nat Prod Res"},{"key":"1966_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147\u201360. https:\/\/doi.org\/10.1016\/j.semcancer.2019.05.012.","journal-title":"Semin Cancer Biol"},{"key":"1966_CR16","doi-asserted-by":"publisher","first-page":"394632024130808","DOI":"10.1177\/03946320241308082","volume":"38","author":"H Liu","year":"2024","unstructured":"Liu H, Li Z, Xu B, Li Z, Yang X, Luo J. Curcumin suppresses metastasis, invasion, and proliferation in osteosarcoma cells by regulating the EGFR\/Src signaling axis. Int J Immunopathol Pharmacol. 2024;38:3946320241308082. https:\/\/doi.org\/10.1177\/03946320241308082.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"1966_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12032-022-01944-0","volume":"40","author":"Y Wang","year":"2023","unstructured":"Wang Y, Luo X, Wu N, Liao Q, Wang J. SRC-3\/TRAF4 facilitates ovarian cancer development by activating the PI3K\/AKT signaling pathway. Med Oncol. 2023;40(2):76. https:\/\/doi.org\/10.1007\/s12032-022-01944-0.","journal-title":"Med Oncol"},{"issue":"1","key":"1966_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ygyno.2020.10.010","volume":"160","author":"S Elayapillai","year":"2021","unstructured":"Elayapillai S, Ramraj S, Benbrook DM, Bieniasz M, Wang L, Pathuri G, et al. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021;160(1):302\u201311. https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.010.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1966_CR19","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.bbrc.2004.02.171","volume":"316","author":"M Kaneuchi","year":"2004","unstructured":"Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, et al. Expression and methylation status of 14\u20133-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun. 2004;316(4):1156\u201362. https:\/\/doi.org\/10.1016\/j.bbrc.2004.02.171.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"1966_CR20","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/IGC.0b013e3181a83f1d","volume":"19","author":"B Li","year":"2009","unstructured":"Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N, et al. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer. 2009;19(8):1347\u201352. https:\/\/doi.org\/10.1111\/IGC.0b013e3181a83f1d.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"1966_CR21","first-page":"959","volume":"33","author":"K Hua","year":"2008","unstructured":"Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y. Estrogen and progestin regulate metastasis through the PI3K\/AKT pathway in human ovarian cancer. Int J Oncol. 2008;33(5):959\u201367.","journal-title":"Int J Oncol"},{"issue":"5","key":"1966_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11307-007-0105-4","volume":"9","author":"AM Lutz","year":"2007","unstructured":"Lutz AM, Ray P, Willmann JK, Drescher C, Gambhir SS. 2-deoxy-2-[F-18]fluoro-D-glucose accumulation in ovarian carcinoma cell lines. Mol Imaging Biol. 2007;9(5):260\u20136. https:\/\/doi.org\/10.1007\/s11307-007-0105-4.","journal-title":"Mol Imaging Biol"},{"issue":"10","key":"1966_CR23","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.febslet.2012.04.007","volume":"586","author":"T Yasukagawa","year":"2012","unstructured":"Yasukagawa T, Niwa Y, Simizu S, Umezawa K. Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells. FEBS Lett. 2012;586(10):1504\u20139. https:\/\/doi.org\/10.1016\/j.febslet.2012.04.007.","journal-title":"FEBS Lett"},{"issue":"23","key":"1966_CR24","doi-asserted-by":"publisher","first-page":"9143","DOI":"10.3390\/ijms21239143","volume":"21","author":"A Szyposzynska","year":"2020","unstructured":"Szyposzynska A, Bielawska-Pohl A, Krawczenko A, Doszyn O, Paprocka M, Klimczak A. Suppression of ovarian cancer cell growth by AT-MSC microvesicles. Int J Mol Sci. 2020;21(23):9143. https:\/\/doi.org\/10.3390\/ijms21239143.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1966_CR25","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/0008-5472.CAN-05-1785","volume":"66","author":"JH Choi","year":"2006","unstructured":"Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res. 2006;66(7):3912\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1785.","journal-title":"Cancer Res"},{"key":"1966_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00945-y","author":"Y Bordon","year":"2023","unstructured":"Bordon Y. A protective role for interferon-\u03b5 in ovarian cancer. Nat Rev Immunol. 2023. https:\/\/doi.org\/10.1038\/s41577-023-00945-y.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1966_CR27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1471-4159.2008.05318.x","volume":"105","author":"CY Wu","year":"2008","unstructured":"Wu CY, Hsieh HL, Sun CC, Tseng CP, Yang CM. IL-1 beta induces prommp-9 expression via c-Src-dependent PDGFR\/PI3K\/Akt\/p300 cascade in rat brain astrocytes. J Neurochem. 2008;105(4):1499\u2013512. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05318.x.","journal-title":"J Neurochem"},{"issue":"2","key":"1966_CR28","doi-asserted-by":"publisher","first-page":"e2870","DOI":"10.1002\/brb3.2870","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, Chen T, Wang Y, Meng J, Tan G, Zhao Q, et al. Oxidative stress disrupts the cytoskeleton of spinal motor neurons. Brain Behav. 2023;13(2):e2870. https:\/\/doi.org\/10.1002\/brb3.2870.","journal-title":"Brain Behav"},{"key":"1966_CR29","doi-asserted-by":"publisher","unstructured":"Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Parnis, F., Atduev, V., Buchschacher, G. L., Jr, Gafanov, R., Corrales, L., Borre, M., Stroyakovskiy, D., Alves, G. V., Bournakis, E., Puente, J., Harle-Yge, M. L., \u2026 de Bono, J. S. (2021). Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet (London, England), 398(10295), 131\u2013142. https:\/\/doi.org\/10.1016\/S0140-6736(21)00580-8","DOI":"10.1016\/S0140-6736(21)00580-8"},{"issue":"3","key":"1966_CR30","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.3892\/mmr.2015.3784","volume":"12","author":"J Xiao","year":"2015","unstructured":"Xiao J, Xu M, Hou T, Huang Y, Yang C, Li J. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling. Mol Med Rep. 2015;12(3):3249\u201356. https:\/\/doi.org\/10.3892\/mmr.2015.3784.","journal-title":"Mol Med Rep"},{"issue":"18","key":"1966_CR31","doi-asserted-by":"publisher","first-page":"8716","DOI":"10.1158\/0008-5472.CAN-06-3731","volume":"67","author":"X Li","year":"2007","unstructured":"Li X, Shen L, Zhang J, et al. Degradation of HER2 by Cbl-based chimeric ubiquitin ligases. Cancer Res. 2007;67(18):8716\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3731.","journal-title":"Cancer Res"},{"issue":"3","key":"1966_CR32","doi-asserted-by":"publisher","first-page":"109156","DOI":"10.1016\/j.isci.2024.109156","volume":"27","author":"W Zhang","year":"2024","unstructured":"Zhang W, Chen S, Ma B, et al. Trifluoperazine regulates blood-brain barrier permeability via the MLCK\/p-MLC pathway to promote ischemic stroke recovery. iScience. 2024;27(3):109156. https:\/\/doi.org\/10.1016\/j.isci.2024.109156.","journal-title":"iScience"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-01966-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01966-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01966-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:52:35Z","timestamp":1773057155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-01966-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1966"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-01966-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7528900\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with the guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of Nanchang Royo Biotech Co., Ltd. (Approval No: RTE2024083002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}